Kenvue Stock News

Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a more intense spotlight coming into these results after reports emerged that activist investor Starboard Value has taken a stake and is eyeing changes.

Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bonnie Herzog - Goldman Sachs Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Peter Grom - UBS Filippo Falorni - Citi Steve Powers - Deutsche Bank Keith Devas - Jefferies Nik Modi - RBC Ca...

Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from activist hedge fund Starboard Value.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Neutrogena® is establishing multi-year partnerships with Dr. Dhaval Bhanusali, and Dr. Muneeb Shah.

Can tinkering around the edges actually make this stock more attractive?

While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.

Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.